vs
Side-by-side financial comparison of REGIS CORP (RGS) and Vericel Corp (VCEL). Click either name above to swap in a different company.
Vericel Corp is the larger business by last-quarter revenue ($92.9M vs $57.1M, roughly 1.6× REGIS CORP). Vericel Corp runs the higher net margin — 25.0% vs 0.8%, a 24.2% gap on every dollar of revenue. On growth, Vericel Corp posted the faster year-over-year revenue change (23.3% vs 22.3%). Vericel Corp produced more free cash flow last quarter ($12.8M vs $891.0K). Over the past eight quarters, Vericel Corp's revenue compounded faster (34.6% CAGR vs 7.8%).
REGIS CORPRGSEarnings & Financial Report
Regis Corporation is an American operator of hair salons. As of August 2021, it has 5,563 franchised and 276 company-owned salons. Its headquarters are in Minneapolis, Minnesota.
Vericel Corporation is a publicly traded American biopharmaceutical company which was known prior to October 2014 as Aastrom Bio. Aastrom Bio was formed in 1989 in Ann Arbor, Michigan.
RGS vs VCEL — Head-to-Head
Income Statement — Q2 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $57.1M | $92.9M |
| Net Profit | $456.0K | $23.2M |
| Gross Margin | — | 78.7% |
| Operating Margin | 10.8% | 24.1% |
| Net Margin | 0.8% | 25.0% |
| Revenue YoY | 22.3% | 23.3% |
| Net Profit YoY | -94.0% | 17.3% |
| EPS (diluted) | $0.16 | $0.46 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $57.1M | $92.9M | ||
| Q3 25 | $59.0M | $67.5M | ||
| Q2 25 | $60.4M | $63.2M | ||
| Q1 25 | $57.0M | $52.6M | ||
| Q4 24 | $46.7M | $75.4M | ||
| Q3 24 | $46.1M | $57.9M | ||
| Q2 24 | $49.4M | $52.7M | ||
| Q1 24 | $49.2M | $51.3M |
| Q4 25 | $456.0K | $23.2M | ||
| Q3 25 | $1.4M | $5.1M | ||
| Q2 25 | $116.5M | $-553.0K | ||
| Q1 25 | $250.0K | $-11.2M | ||
| Q4 24 | $7.6M | $19.8M | ||
| Q3 24 | $-853.0K | $-901.0K | ||
| Q2 24 | $91.2M | $-4.7M | ||
| Q1 24 | $-2.3M | $-3.9M |
| Q4 25 | — | 78.7% | ||
| Q3 25 | — | 73.5% | ||
| Q2 25 | — | 73.7% | ||
| Q1 25 | — | 69.0% | ||
| Q4 24 | — | 77.6% | ||
| Q3 24 | — | 71.9% | ||
| Q2 24 | — | 69.5% | ||
| Q1 24 | — | 68.9% |
| Q4 25 | 10.8% | 24.1% | ||
| Q3 25 | 10.0% | 5.1% | ||
| Q2 25 | 12.1% | -3.2% | ||
| Q1 25 | 8.8% | -24.3% | ||
| Q4 24 | 11.8% | 24.5% | ||
| Q3 24 | 4.6% | -4.3% | ||
| Q2 24 | — | -11.5% | ||
| Q1 24 | 8.3% | -10.7% |
| Q4 25 | 0.8% | 25.0% | ||
| Q3 25 | 2.3% | 7.5% | ||
| Q2 25 | 192.9% | -0.9% | ||
| Q1 25 | 0.4% | -21.4% | ||
| Q4 24 | 16.4% | 26.3% | ||
| Q3 24 | -1.9% | -1.6% | ||
| Q2 24 | 184.7% | -8.9% | ||
| Q1 24 | -4.7% | -7.5% |
| Q4 25 | $0.16 | $0.46 | ||
| Q3 25 | $0.49 | $0.10 | ||
| Q2 25 | $43.67 | $-0.01 | ||
| Q1 25 | $0.08 | $-0.23 | ||
| Q4 24 | $2.71 | $0.40 | ||
| Q3 24 | $-0.36 | $-0.02 | ||
| Q2 24 | $38.40 | $-0.10 | ||
| Q1 24 | $-1.00 | $-0.08 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $18.4M | $137.5M |
| Total DebtLower is stronger | $113.3M | — |
| Stockholders' EquityBook value | $188.7M | $354.6M |
| Total Assets | $588.3M | $488.0M |
| Debt / EquityLower = less leverage | 0.60× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $18.4M | $137.5M | ||
| Q3 25 | $16.6M | $135.4M | ||
| Q2 25 | $17.0M | $116.9M | ||
| Q1 25 | $13.3M | $112.9M | ||
| Q4 24 | $10.2M | $116.2M | ||
| Q3 24 | $6.3M | $101.7M | ||
| Q2 24 | $10.1M | $102.5M | ||
| Q1 24 | $5.9M | $110.6M |
| Q4 25 | $113.3M | — | ||
| Q3 25 | $111.3M | — | ||
| Q2 25 | $110.8M | — | ||
| Q1 25 | $112.0M | — | ||
| Q4 24 | $111.5M | — | ||
| Q3 24 | $95.2M | — | ||
| Q2 24 | $99.5M | — | ||
| Q1 24 | $179.7M | — |
| Q4 25 | $188.7M | $354.6M | ||
| Q3 25 | $187.6M | $321.9M | ||
| Q2 25 | $185.6M | $306.8M | ||
| Q1 25 | $68.6M | $295.5M | ||
| Q4 24 | $66.7M | $292.0M | ||
| Q3 24 | $56.4M | $257.5M | ||
| Q2 24 | $56.8M | $243.0M | ||
| Q1 24 | $-35.8M | $233.9M |
| Q4 25 | $588.3M | $488.0M | ||
| Q3 25 | $592.1M | $453.3M | ||
| Q2 25 | $599.0M | $435.6M | ||
| Q1 25 | $511.2M | $424.6M | ||
| Q4 24 | $530.1M | $432.7M | ||
| Q3 24 | $508.9M | $390.4M | ||
| Q2 24 | $530.5M | $376.8M | ||
| Q1 24 | $543.7M | $356.7M |
| Q4 25 | 0.60× | — | ||
| Q3 25 | 0.59× | — | ||
| Q2 25 | 0.60× | — | ||
| Q1 25 | 1.63× | — | ||
| Q4 24 | 1.67× | — | ||
| Q3 24 | 1.69× | — | ||
| Q2 24 | 1.75× | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $1.7M | $15.0M |
| Free Cash FlowOCF − Capex | $891.0K | $12.8M |
| FCF MarginFCF / Revenue | 1.6% | 13.8% |
| Capex IntensityCapex / Revenue | 1.4% | 2.4% |
| Cash ConversionOCF / Net Profit | 3.65× | 0.65× |
| TTM Free Cash FlowTrailing 4 quarters | $14.9M | $24.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $1.7M | $15.0M | ||
| Q3 25 | $2.3M | $22.1M | ||
| Q2 25 | $6.8M | $8.2M | ||
| Q1 25 | $6.2M | $6.6M | ||
| Q4 24 | $2.1M | $22.2M | ||
| Q3 24 | $-1.3M | $10.2M | ||
| Q2 24 | $5.1M | $18.5M | ||
| Q1 24 | $-277.0K | $7.2M |
| Q4 25 | $891.0K | $12.8M | ||
| Q3 25 | $1.9M | $19.5M | ||
| Q2 25 | $6.2M | $81.0K | ||
| Q1 25 | $5.9M | $-7.6M | ||
| Q4 24 | $1.7M | $8.5M | ||
| Q3 24 | $-1.4M | $-9.2M | ||
| Q2 24 | $5.1M | $1.8M | ||
| Q1 24 | $-326.0K | $-6.8M |
| Q4 25 | 1.6% | 13.8% | ||
| Q3 25 | 3.2% | 28.8% | ||
| Q2 25 | 10.3% | 0.1% | ||
| Q1 25 | 10.3% | -14.5% | ||
| Q4 24 | 3.6% | 11.2% | ||
| Q3 24 | -3.0% | -15.9% | ||
| Q2 24 | 10.3% | 3.4% | ||
| Q1 24 | -0.7% | -13.3% |
| Q4 25 | 1.4% | 2.4% | ||
| Q3 25 | 0.7% | 3.9% | ||
| Q2 25 | 0.9% | 12.9% | ||
| Q1 25 | 0.6% | 27.0% | ||
| Q4 24 | 0.9% | 18.3% | ||
| Q3 24 | 0.0% | 33.5% | ||
| Q2 24 | 0.0% | 31.8% | ||
| Q1 24 | 0.1% | 27.3% |
| Q4 25 | 3.65× | 0.65× | ||
| Q3 25 | 1.68× | 4.35× | ||
| Q2 25 | 0.06× | — | ||
| Q1 25 | 24.80× | — | ||
| Q4 24 | 0.28× | 1.12× | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.06× | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
VCEL
| MACI Implants And Kits | $84.1M | 90% |
| Other | $8.8M | 10% |
